» Articles » PMID: 25690340

Human Monoclonal Antibody Fragments Targeting Matrilin-3 in Growth Plate Cartilage

Overview
Journal Pharm Res
Specialties Pharmacology
Pharmacy
Date 2015 Feb 19
PMID 25690340
Citations 2
Authors
Affiliations
Soon will be listed here.
Abstract

Purpose: Many genetic disorders, including chondrodysplasias, and acquired disorders impair growth plate function, resulting in short and sometimes malformed bones. There are multiple endocrine and paracrine factors that promote chondrogenesis at the growth plate, which could potentially be used to treat these disorders. Targeting these growth factors specifically to the growth plate might augment the therapeutic skeletal effect while diminishing undesirable effects on non-target tissues.

Methods: Using yeast display technology, we selected single-chain variable antibody fragments that bound to human and mouse matrilin-3, an extracellular matrix protein specifically expressed in cartilage tissue. The ability of the selected antibody fragments to bind matrilin-3 and to bind cartilage tissue in vitro and in vivo was assessed by ELISA and immunohistochemistry.

Results: We identified antibody fragments that bound matrilin-3 with high affinity and also bound with high tissue specificity to cartilage homogenates and to cartilage structures in mouse embryo sections. When injected intravenously in mice, the antibody fragments specifically homed to cartilage.

Conclusions: Yeast display successfully selected antibody fragments that are able to target cartilage tissue in vivo. Coupling these antibodies to chondrogenic endocrine and paracrine signaling molecules has the potential to open up new pharmacological approaches to treat childhood skeletal growth disorders.

Citing Articles

Efficacy of cartilage-targeted IGF-1 in a mouse model of growth hormone insensitivity.

Tailor K, van Ree J, Stowe T, Ventura B, Sisk C, Courtis J Front Endocrinol (Lausanne). 2025; 15:1523931.

PMID: 39850478 PMC: 11756323. DOI: 10.3389/fendo.2024.1523931.


Loss-of-function variant in SPIN4 causes an X-linked overgrowth syndrome.

Lui J, Wagner J, Zhou E, Dong L, Barnes K, Jee Y JCI Insight. 2023; 8(9).

PMID: 36927955 PMC: 10243798. DOI: 10.1172/jci.insight.167074.


Cartilage-Targeted IGF-1 Treatment to Promote Longitudinal Bone Growth.

Lui J, Colbert M, Cheung C, Ad M, Lee A, Zhu Z Mol Ther. 2019; 27(3):673-680.

PMID: 30765323 PMC: 6404097. DOI: 10.1016/j.ymthe.2019.01.017.

References
1.
Agoston H, Khan S, James C, Gillespie J, Serra R, Stanton L . C-type natriuretic peptide regulates endochondral bone growth through p38 MAP kinase-dependent and -independent pathways. BMC Dev Biol. 2007; 7:18. PMC: 1847438. DOI: 10.1186/1471-213X-7-18. View

2.
Canete R, Valle M, Martos R, Sanchez-Carrion A, Canete M, van Donkelaar E . Short-term effects of GH treatment on coagulation, fibrinolysis, inflammation biomarkers, and insulin resistance status in prepubertal children with GH deficiency. Eur J Endocrinol. 2012; 167(2):255-60. DOI: 10.1530/EJE-12-0214. View

3.
Olney R . C-type natriuretic peptide in growth: a new paradigm. Growth Horm IGF Res. 2006; 16 Suppl A:S6-14. DOI: 10.1016/j.ghir.2006.03.016. View

4.
Lui J, Nilsson O, Chan Y, Palmer C, Andrade A, Hirschhorn J . Synthesizing genome-wide association studies and expression microarray reveals novel genes that act in the human growth plate to modulate height. Hum Mol Genet. 2012; 21(23):5193-201. PMC: 3490510. DOI: 10.1093/hmg/dds347. View

5.
Yoon B, Ovchinnikov D, Yoshii I, Mishina Y, Behringer R, Lyons K . Bmpr1a and Bmpr1b have overlapping functions and are essential for chondrogenesis in vivo. Proc Natl Acad Sci U S A. 2005; 102(14):5062-7. PMC: 555995. DOI: 10.1073/pnas.0500031102. View